A-S Moldovan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

A-S Moldovan

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Journal of Neurology|February 10, 2019

Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathyK Logmin, A S Moldovan, S Elben, et al.

Zeitschrift Fur Rheumatologie|May 29, 2020

[Muscle weakness and CK elevation: is it myositis?]A Kernder, J Mucke, A-S Moldovan, et al.

Nuklearmedizin. Nuclear Medicine|May 20, 2015

Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimationW Jentzen, A-S Moldovan, M Ruhlmann, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Journal of Neurology|February 10, 2019

Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathyK Logmin, A S Moldovan, S Elben, et al.

Zeitschrift Fur Rheumatologie|May 29, 2020

[Muscle weakness and CK elevation: is it myositis?]A Kernder, J Mucke, A-S Moldovan, et al.

Nuklearmedizin. Nuclear Medicine|May 20, 2015

Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimationW Jentzen, A-S Moldovan, M Ruhlmann, et al.

Pageof 1